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Abstract: Quantification of the lipid content in liposomal adjuvants for subunit vaccine formulation 14 
is of extreme importance, since this concentration impacts both efficacy and stability. In this paper, 15 
we outline a high performance liquid chromatography-evaporative light scattering detector (HPLC-16 
ELSD) method that allows for the rapid and simultaneous quantification of lipid concentrations 17 
within liposomal systems prepared by three liposomal manufacturing techniques (lipid film 18 
hydration, high shear mixing, and microfluidics). The ELSD system was used to quantify four lipids: 19 
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), cholesterol, 20 
dimethyldioctadecylammonium (DDA) bromide, and D-(+)-trehalose 6,6′-dibehenate (TDB). The 21 
developed method offers rapidity, high sensitivity, direct linearity, and a good consistency on the 22 
responses (R2 > 0.993 for the four lipids tested). The corresponding limit of detection (LOD) and limit 23 
of quantification (LOQ) were 0.11 and 0.36 mg/mL (DMPC), 0.02 and 0.80 mg/mL (cholesterol), 0.06 24 
and 0.20 mg/mL (DDA), and 0.05 and 0.16 mg/mL (TDB), respectively. HPLC-ELSD was shown to 25 
be a rapid and effective method for the quantification of lipids within liposome formulations 26 
without the need for lipid extraction processes. 27 
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 29 
1. Introduction 30 
Liposomes continue to be a major focus in drug delivery research due to their ability to enhance 31 
the delivery and targeting of a wide range of drugs and vaccines. In the majority of products 32 
approved for clinical use, a combination of a phosphatidylcholine and cholesterol is used, with some 33 
examples outlined in Table 1. However, as new applications are developed, and new lipids become 34 
available, we are able to exploit a vast range of lipid combinations so as to further enhance the efficacy 35 
of these formulations. For example, recent collaborative work from our laboratories has focused on 36 
the use of cationic liposomal adjuvants to enhance the delivery and efficacy of sub-unit antigens. The 37 
adjuvants are based on a two-component vesicle formulation, which is the combination of the cationic 38 
lipid dimethyldioctadecylammonium (DDA) and D-(+)-trehalose 6,6′-dibehenate (TDB). DDA is a 39 
synthetic amphiphile discovered to have adjuvant properties by Gall in the mid-1960s [1]. It contains 40 
a quaternary ammonium group with two 18-carbon-long alkyl chains (forming the hydrophobic 41 
moiety) and two methyl groups, which, together with the ammonium group, form the polar head 42 
group. The positively-charged head group carries a monovalent counterion, typically bromide or 43 
chloride. TDB is a synthetic analog of trehalose-6,6-dimycolate, an immunostimulatory component 44 
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of Mycobacterium tuberculosis. It has two 22 carbon saturated fatty-acid chains (behenyl), each 45 
replacing the branched mycobacterial mycolic acids of >70 carbons. These two behenyl chains are 46 
linked by ester bonds to carbon number six of each of the two glucopyranose rings making up the 47 
trehalose head group. TDB has been shown to retain much of the bioactivity of the native form, while 48 
showing less toxicity as a result of the shorter fatty acid chains [2,3]. Formulation of vesicles from 49 
DDA alone produces vesicles able to induce cell-mediated immunity and delayed-type 50 
hypersensitivity. Along with its cationic nature and surfactant properties, it has been shown to be an 51 
effective adjuvant in numerous applications, including mucosal immunization [4], gene delivery 52 
[5,6], and subunit vaccine delivery [7–9]. However the combination of DDA and TDB within the 53 
liposome formulation was shown to further enhance the adjuvant properties of the liposomes [10]. 54 
This lipid combination is known as the cationic adjuvant formulation (CAF) 01. 55 
Table 1. Examples of approved liposome formulations. 56 
Product Name Drug Delivered Lipid Composition 
AmBisome® Amphotericin B 
Hydrogenated soy phosphatidylcholine, 
cholesterol, disteraroylphosphatidyl glycerol, and α 
tocopherol 
Caelyx®/ Doxil® Doxorubicin 
PEGylated distearoylphosphatidyl ethanolamine, 
hydrogenated soy phosphatidylcholine, and 
cholesterol  
DaunoXome® Daunorubicin Distearylphosphatidylcholine and cholesterol  
Definity® Octafluoropropane 
Dipalmitoylphosphatidic acid, 
dipalmitoylphosphatidylcholine, and PEG-500 
dipalmitoyl phosphatidyletholamine 
DepoCyte® Cytarabine 
Dioleoylphosphatidylcholine, cholesterol, 
dipalmitoylphosphatidylglycerol, and triolein 
DepoDur® Morphine sulfate 
Dioleoyl phosphatidylcholine, dipalmitoyl 
phosphatidylglycerol, cholesterol, and triolein 
Epaxal® Inactivated hepatitis A virus 
Phosphatidylcholine, cephalin, and purified virus 
surface antigens 
Inflexal V® 
Influenza haemagglutinin 
glycoprotein and 
neuraminidase 
Similar to Epaxal; phosphatidylcholine, cephalin, 
and purified virus surface antigens 
Myocet® Doxorubicin Egg phosphatidylcholine and cholesterol 
Visudyne® Vereporfin 
Dimyristoylphosphatidylcholine and egg 
phosphatidylglycerol 
Given the importance of lipid composition in liposome formulations in terms of their drug 57 
incorporation and release properties, pharmacokinetic properties, and their stability, the 58 
quantification of lipid components is a key product attribute. However, the development of rapid 59 
and simple quantitative tools for the analysis of lipids has been slow. This is primarily due to the 60 
absence of easily detectable functional groups (e.g., chromophores) on most lipids, which makes them 61 
difficult to measure quantitatively using the more common types of detectors. Therefore, while high-62 
performance liquid chromatography (HPLC) is the technique of choice for the efficient separation of 63 
lipid components based on different chain lengths, head group composition, and polarities [11–16], 64 
appropriate detectors for lipids are required for the quantification of these lipids upon separation. To 65 
achieve this, mass detectors such as evaporative light scattering detectors (ELSD) can be used [17]. 66 
ELSD is used for the quantification of non-volatile components dissolved in volatile solvents. In this 67 
method, a nebuliser evaporates the solvent (mobile phase) inside the heating chamber. Solvent 68 
droplets condense within the chamber and are removed from the system. Meanwhile, the non-69 
volatile compound (analyte) becomes a mist of small particles which continue moving, by means of 70 
a stream of compressed air, towards the detector. When sample particles pass through the optical 71 
cell, a laser beam illuminates the sample, and when the laser hits the particles, the intensity of the 72 
scattered light is measured by a detector (Figure 1). The detector can quantify the amount of sample 73 
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according to the scattered light detected. This method is constrained to a sufficiently volatile solvent 74 
with a different volatility than the analyte, and for the separation of lipid classes, gradient elution is 75 
often required. 76 
 77 
Figure 1. Schematic representation of the mechanism of an evaporative light scattering detector 78 
(ELSD). First, the chromatographic eluate passes through the nebulizer and mixes with the nebulizing 79 
gas (N2), causing dispersion of droplets; subsequently, droplets enter into the nebulizing chamber 80 
where the mobile phase evaporates and condenses, being removed as waste; Finally, the analyte 81 
crosses an optical cell, a laser beam penetrates the particles, and the scattered light is detected and 82 
converted into a signal. 83 
In addition to considering quantification, lipid degradation is also an important factor that needs 84 
to be considered. The main route of phospholipid degradation is hydrolysis [18]. This can occur 85 
rapidly, and can be promoted by increases in temperature and/or harsh processing conditions, such 86 
as sonication. However, the use of bath sonication may circumvent this issue [19]. The products of 87 
the hydrolysis of phospholipids are lysolipids, and they have a detergent effect which can interfere 88 
with the liposome bilayer. This is due to the lysolipids stabilizing pores in the membrane, thereby 89 
enhancing the permeability of the bilayer and promoting liposome bilayer fusion [20,21]. This process 90 
can occur even at low lysolipid concentrations [22]. Lipids can also be susceptible to degradation via 91 
oxidation of polyunsaturated hydrocarbon chains and ester hydrolysis, producing oxidized 92 
lysophosphatide and free fatty acid derivatives. These products of oxidation also have an effect on 93 
membrane permeability [23]. However, it has been shown that the presence of cholesterol within a 94 
liposome formulation can reduce oxidation by reducing lipid-bilayer hydration [24]. To quantify 95 
degradation, previous work has centered around using NMR and mass spectrometry to analyze the 96 
products of lipid degradation; however, these methods can be both time consuming and expensive 97 
to run [25]. 98 
Given that the choice of lipid composition directly impacts liposome efficacy and stability, the 99 
aim of this current study was to develop and validate a rapid quantification method for lipids that 100 
does not require an initial lipid extraction process. This method was used to quantify lipids within 101 
the DDA:TDB liposome adjuvant system and also to demonstrate the general procedures such that 102 
they can be applied to a wide range of lipids used by liposomologists. As such, we demonstrate the 103 
quantification of four lipids using HPLC-ELSD: DDA, TDB, DMPC, and cholesterol, with a detailed 104 
focus on cholesterol given that it is the most common component of liposome systems. We also 105 
consider the ability of this HPLC-ELSD method to detect phospholipid lipid degradation. 106 
2. Materials and Methods 107 
2.1. Materials 108 
The cationic surfactant dimethyldioctadecylammonium (DDA) bromide, neutral lipid 1,2-109 
dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and the immunopotentiator α,α′-trehalose 6,6′-110 
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dibehenate (TDB) were obtained from Avanti Polar Lipids Inc., Alabaster, AL, US. Cholesterol was 111 
obtained from Sigma-Aldrich Company Ltd., Poole, UK. 2-amino-2-(hydroximethyl)-1,3-propanediol 112 
(Trizma base®) was obtained from ICN Biomedicals Inc., Aurora, Ohio, US, and ultrapure water was 113 
obtained from a Milli-Q purification system (Millipore, Billerica, MA, US). All other reagents, such 114 
as chloroform, methanol, isopropyl alcohol, phosphate-buffered saline (PBS), and trifluoroacetic acid 115 
(TFA) were of analytical grade and purchased from commercial suppliers. 116 
2.2. Manufacturing of Liposomes 117 
Liposomal formulations were prepared in triplicate (n = 3) by using three different methods. 118 
With the traditional lipid film hydration (LH) method [26] weighed amounts of DDA (10 mg/mL), 119 
TDB (2 mg/mL), cholesterol (2 mg/mL), and DMPC (10 mg/mL) were dissolved in a mixture of 120 
chloroform:methanol (v/v 9:1) for the preparation of the stock solutions. The required amount of lipid 121 
solution was transferred to a round-bottom flask to reach the desired lipid concentration and mixed; 122 
DDA and TDB concentrations were fixed at 2.5 and 0.5 mg/mL, respectively, and cholesterol was 123 
added to the CAF01 formulation at a concentration of 0.8 mg/mL. In the third formulation, DDA was 124 
replaced by DMPC and kept at the original concentration. Organic solvent was removed under 125 
vacuum with a rotary evaporator for 15 min at 200 revolutions per minute (rpm) at 37 °C in a water 126 
bath. Afterwards, the lipid film was dried with a gentle stream of N2 in order to remove any trace of 127 
organic solvent. Then, the lipid film was hydrated with 1 mL of 10 mM Tris buffer (pH 7.4) at 60 °C 128 
(DDA has the highest Tm (~47 °C) of all four lipids; thus, hydration of the lipid film was at 10 °C above 129 
it) with vortexing every 5 min for 20 min. 130 
After preparation by the thin lipid film, the formed liposomes were subjected to probe sonication 131 
(MSE Soniprep 150 plus with MSE probe 100, MSE, London, UK) at an amplitude of 10 amps. The 132 
liposomes were sonicated for 10 min. The liposome samples were placed in 1.5 mL Eppendorf tubes 133 
and then subjected to centrifugation (Grant-bio PCV-3000, Grant, Shepreth, UK) at 1500 rpm for 20 134 
min to remove any large contaminants from solution. Supernatant (100 µL) was collected for size 135 
analysis. 136 
The thin film method followed by high shear mixing (HSM) (SilentCrusher M, Heidolph 137 
instruments, Schwabach, Germany) [27]: after preparation of the thin lipid film, formation of 138 
liposomes was carried out by hydration of the film with 1 mL of Tris buffer (10 mM, pH 7.4) and high 139 
shear mixing at 60 °C. The head of the HSM was immersed in the formulation, and samples were 140 
homogenized at high speed (240,000 rpm) for 15 min. 141 
Microfluidics (MF) (Nanoassemblr™ Benchtop, Precision Nanosystems Inc., Vancouver, British 142 
Columbia, Canada) [28]: in order to produce DDA or DMPC-containing liposomes, lipids were 143 
dissolved in the organic solvent (isopropyl alcohol) at the concentrations mentioned above. Organic 144 
and aqueous phase (Tris buffer 10 mM, pH 7.4) were heated to 60 °C before and during injection into 145 
the system. Control parameters of the microfluidics system were varied in order to obtain the smallest 146 
liposome size. After liposome preparation, samples were dialyzed (membrane cut off 3500 Da, 147 
Medicell membranes, Ltd., London, UK) against 200 mL of Tris buffer during 1 h in order to remove 148 
the organic solvent. 149 
2.3. HPLC Method 150 
Quantification of the lipid recovery was performed by reverse phase high performance liquid 151 
chromatography (HPLC) (YL instrument, Anyang, Korea) using a SEDEX 90LT ELSD detector (Sedex 152 
Sedere, Alfortville, France) connected to the instrument. The use of evaporative light-scattering 153 
detectors can result in limited direct linearity, and when larger concentration ranges are required, a 154 
standard log–log transformation can be used. However, within our studies, we use the SEDEX 90LT, 155 
which offers a notably increased overall direct linearity range. A Phenomenex Luna column 5 µm 156 
C18(2) 4.60 mm inner diameter and 150 mm length with 100 Ă pore size (Phenomenex, Macclesfield 157 
UK.) was used as stationary phase, since a C18 column increases the retention of non-polar analytes. 158 
Separation of the lipids was carried out using an elution gradient analysis displayed in Table 2. 159 
Mobile phase A consisted of 0.1% TFA in water, whereas mobile phase B consisted of 100% methanol. 160 
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Standard lipid solutions were dissolved in chloroform:methanol (9:1 v/v) prior to injection, whereas 161 
liposome formulations were injected after manufacturing with no prior modification. The HPLC-162 
ELSD settings were kept constant as follows: 30 µL injection volume in a partial loopfill injection 163 
mode, 100 µL loop volume and 15 µL tubing volume. Column temperature was maintained at 35 °C, 164 
whereas the ELSD temperature was set at 52 °C in all the runs. Nitrogen was used as a carrier gas at 165 
3.5 psi inlet pressure. Chromatograms were analyzed with Clarity DataApex version 4.0.3.876 166 
software. 167 
2.4. Standard Solutions 168 
Standard solutions of cholesterol (0.025 to 1 mg/mL), TDB (0.2 to 1 mg/mL), DDA (0.125 to 2.5 169 
mg/mL), and DMPC (0.25 to 2.5 mg/mL) were prepared in chloroform:methanol (v/v 9:1). Solutions 170 
were injected into the HPLC system prior to each measurement in order to establish the calibration 171 
curves and as a reference check. 172 
Table 2. Gradient elution method for quantitative analysis of cholesterol, 1,2-dimyristoyl-sn-glycero-173 
3-phosphocholine (DMPC), dimethyldioctadecylammonium (DDA), and D-(+)-trehalose 6,6′-174 
dibehenate (TDB). TFA: trifluoroacetic acid. 175 
Time (min) % Eluent A (0.1% TFA in dH2O) % Eluent B (MeOH) Flow Rate (mL/min) 
0 15 85 1.5 
6 0 100 1.5 
25 0 100 1.5 
26 15 85 1.5 
35 15 85 1.5 
2.5. Method Validation 176 
The method was validated by assessing the linearity, reproducibility, robustness, accuracy, limit 177 
of detection (LOD), and limit of quantification (LOQ). For quantification, established calibration 178 
curves were used. The system was flushed with 100% methanol before each use for 30 min until a 179 
stable baseline was observed. 180 
2.6. HPLC Lipid Degradation Method 181 
Separation of lipid degradation products was carried out using an isocratic flow method (85% 182 
methanol and 15% of 0.1% TFA in water) at a flow rate of 1 mL/min allowed the lipids to separate 183 
down the column. HPLC-ELSD settings were kept constant as outlined in Section 2.3 using the 184 
Phenomenex Luna 5 µm C8(2) 4.60 mm inner diameter and 150 mm length with 100 Ă pore size. The 185 
specificity of the method was tested by conducting forced degradation of a liposome formulation 186 
using 0.1N HCl at room temperature for four days, as previously described by Zhong  187 
and Zhang [29]. 188 
3. Results and Discussion 189 
3.1. Lipid Quantification Using HPLC-ELSD: Method Development 190 
The cationic lipid DDA, and other neutral lipids such as cholesterol, DMPC, and the 191 
immunopotentiator TDB are common compounds of liposomal adjuvant formulations. Lipid 192 
quantification is of great importance for the stability and efficacy of liposomal formulations. 193 
Therefore, an HPLC-ELSD method for the quantification of these lipids was developed in order to 194 
achieve the analysis of all four lipids at the same time. Figure 2 shows the chromatogram of a mixture 195 
of the four lipids and their chemical structures. DDA is the least hydrophobic lipid and eluted at 7.1 196 
min, followed by DMPC at 9.2 min, cholesterol at 10.9 min, and finally TDB at 19.9 min due to its 197 
hydrophobicity. Analysis time was set at 35 min, even though all four lipids eluted within the first 20 198 
min, in order give time to the column to equilibrate. Elution peaks were well separated with a stable 199 
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baseline. TDB peaks were short and wide, whereas DDA, DMPC, and cholesterol peaks were high 200 
and sharp. Chromatographic methods have to be tested in order to guarantee trustworthy and solid 201 
data. Therefore, validation of the HPLC-ELSD method was performed according to the International 202 
Conference of Harmonization (ICH) guidelines Q2 (R1) [30] in terms of linearity, sensitivity, accuracy, 203 
reproducibility, and robustness, and as an example, a complete validation protocol for cholesterol is 204 
outlined in Figure 3. 205 
 206 
Figure 2. ELSD-detected HPLC chromatogram of DDA (1.5 mg/mL), DMPC (1.5 mg/mL), Cholesterol 207 
(2 mg/mL), and TDB (1 mg/mL). 208 
For the linearity assessment (Figure 3A–D), standard solutions of each lipid were prepared in 209 
chloroform:methanol (9:1 v/v). A different concentration range was chosen for each lipid, based on 210 
the initial concentration used for the preparation of liposomes: for DDA, the concentration ranged 211 
from 0.125–2.5 mg/mL; for DMPC, from 0.25–2.5 mg/mL; for TBD, from 0.2–1 mg/mL; and for 212 
cholesterol, 0.025–1 mg/mL. The mean peak area ± standard deviation (SD) was calculated and 213 
plotted against the known concentration of the standard. ELSDs are known to be non-linear; 214 
however, SEDEX 90LT provides direct linearity and a good consistency on the responses. From 215 
Figure 3A–D it can be seen that all calibration curves display a good linear fit, with correlation 216 
coefficients (R2) greater than 0.993. 217 
Study of the sensitivity of the method was assessed by means of the calculation of the limit of 218 
detection and the limit of quantification (Figure 3E). Values were determined from the standard 219 
deviation of the response (σ) and the slope (S) obtained from the calibration curves carried out during 220 
the linearity assessment. According to the ICH guidelines, a signal-to-noise ratio of three was 221 
assumed for the quantification of the LOD, whereas for the LOQ, a signal-to-noise ratio of ten was 222 
set. Therefore, following Equations (1)–(3), the sensitivity of the method for the detection of DDA, 223 
TDB, DMPC, and cholesterol was calculated. 224 
ߪ ൌ ඨߑ ሺܻ െ ௜ܻሻ
ଶ
݊ െ 2  (1) 
ܮܱܦ ൌ 3ߪܵ  (2) 
ܮܱܳ ൌ 10ߪݏ  (3) 
Pharmaceutics 2016, 8, x FOR PEER REVIEW 7 of 4 
 
The corresponding LOD and LOQ were 0.11–0.36 mg/mL, 0.02–0.80 mg/mL, 0.06–0.20 mg/mL, 225 
and 0.05–0.16 mg/mL for DMPC, cholesterol, DDA, and TDB, respectively (Figure 3E). TDB was the 226 
most difficult lipid to quantify, since the intensity of the peaks and the concentration used for the 227 
formulations was lower compared to the other compounds, which reflects the concentrations used 228 
within liposome formulations. 229 
 230 
Figure 3. Linearity assessment of (A) DMPC (0.25 to 2.5 mg); (B) Cholesterol (0.025 to 1 mg); (C) DDA 231 
(0.125 to 2.5 mg); and (D) TDB (0.2 to 1 mg). The LOD and LOQ for each lipid is shown in (E). Results 232 
represent mean ± SD of triplicate measurements (n = 3). 233 
The repeatability of the method is the determination of how close values are to each other under 234 
identical experimental conditions, and was assessed by determination of the intraday and interday 235 
variability using cholesterol (Figure 4). Cholesterol standards from 0.025 to 1 mg/mL carried out 236 
within the same day (intraday) and over the course of three days (interday) are plotted in Figure 237 
4A,B, respectively. For the linearity assessment, the average peak area ± SD measurements of each 238 
concentration were plotted against the known cholesterol concentration. The results show that the 239 
values have no detectable difference for all the calibration curves carried out at different times on the 240 
same day and also on different days, meaning the method has good precision. 241 
To test the accuracy of the HPLC-ELSD method, spiked samples of cholesterol standards were 242 
prepared and quantified. Figure 4C shows the results of three replicates of cholesterol concentrations 243 
at 0.05, 0.1, and 0.25 mg/mL injected into the HPLC-ELSD system in triplicate (n = 9). The relative 244 
standard deviation (% RSD) and the recovery of cholesterol were calculated for each concentration, 245 
and were within the acceptance limit of ≤5% and 90%–110%, respectively (Figure 4C). 246 
Robustness—which represents the ability of the method to remain unchanged by small 247 
deviations—was demonstrated by variation in the flow rate and column temperature. To consider 248 
this the flow rate, which was initially set at 1.5 mL/min, was changed by ±0.2 mL/min, and Figure 4D 249 
displays the elution peaks of cholesterol by variation of the flow rate. Increased flow rate—which 250 
represents an increased volume and speed of mobile phase through the column—resulted in a faster 251 
elution of cholesterol. In contrast, a decreased flow rate resulted in the later elution of cholesterol 252 
from the column. When the column temperature was modified ±5 °C, small variations in the 253 
cholesterol elution time and column height were seen (Figure 4E). An increase in temperature 254 
accelerates the elution of cholesterol, which can be explained by an increase in the diffusion of the 255 
molecules due to the higher temperature. Due to the changes observed during the robustness 256 
assessment, flow rate and column temperature were fixed at 1.5 mL/min and 35 °C, respectively. 257 
Pharmaceutics 2016, 8, x FOR PEER REVIEW 8 of 4 
 
 258 
Figure 4. Cholesterol quantification case study: (A) intraday variability; (B) interday variability;  259 
(C) accuracy; and robustness with (D) flow rate and (E) temperature. 260 
3.2. Quantification of Lipids within Liposomal Adjuvant Formulations 261 
After method validation, three liposomal formulations were prepared: DDA and TDB 262 
concentrations were fixed at 3.96 and 0.5 mM, respectively, and cholesterol was added to this 263 
formulation at a concentration of 31 mol % in order to increase the fluidity of the membrane bilayer 264 
and favor the formation of liposomes at room temperature. In the third formulation, DDA was 265 
replaced by DMPC. These formulations were prepared using three different manufacturing methods. 266 
Lipid film hydration is the classical method used to prepare liposomes. It has been used since 1960s, 267 
and since then, variation of the method and other methods for liposome preparation have emerged. 268 
Among them are the combination of LH with high shear mixing [27] and microfluidics [31–33]. 269 
Microfluidics manipulates the mixing of fluids in micro-sized channels, allowing for size-controlled 270 
liposome preparation [31]. It has several advantages compared to other methods, such as high 271 
reproducibility and scalability, low cost, and easy control. However, it is important to consider lipid 272 
concentrations post-production of liposomes, given that this can impact the physicochemical 273 
characterization of the resulting liposomes and will determine the performance of these delivery 274 
systems. The results (Figure 5) obtained from each technique showed that larger liposomes were 275 
prepared by the traditional LH method, whereas HSM and MF produced smaller liposomes and more 276 
homogeneous particle size distributions, as would be expected with these methods (Figure 5). 277 
Similarly, as the same lipid composition was used in each method, the zeta potentials for all three 278 
formulations were similar, irrespective of the manufacturing method (Figure 5). Given that the aim 279 
of this research was to develop a rapid procedure for the quantification of lipids within liposomes, 280 
without the need for extraction processes, formulations were injected into the HPLC-ELSD system, 281 
without prior modification, for quantification of the lipid recovery (Figure 5). Lipid quantification 282 
revealed a lipid recovery of 96%, 88%, 93%, and 97% for DDA, TDB, cholesterol, and DMPC, 283 
respectively, after manufacturing using LH. Liposome formulations manufactured using HSM 284 
showed a recovery of 95%, 90%, 99%, and 94% for DDA, TDB, cholesterol, and DMPC, respectively. 285 
Finally, microfluidics exhibited a recovery for DDA, TDB, cholesterol, and DMPC of 100%, 83%, 98%, 286 
and 100% respectively. For the immunopotentiator TDB, the results were more variable than for the 287 
other lipids, but was >80% across the formulations, presumably due to the low concentrations of TDB 288 
used in the formulations. In general, while the method of liposome formulation impacted liposome 289 
characteristics as would be expected, there are no significant differences in the recovery of the lipids 290 
between each of the three methods employed. 291 
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 292 
Figure 5. Lipid recovery, size, polydispersity index (PDI) and zeta potential (ZP) from liposomes 293 
prepared by lipid hydration (LH), high-shear mixing (HSM), and microfluidics (MF). Results 294 
represent the mean ± SD of three replicate batches (n = 3). 295 
3.3. The Use of HPLC-ELSD to Assess Lipid Degradation in Liposome Formulations 296 
To consider if HPLC-ELSD could be used to assess lipid degradation, DMPC liposomes were 297 
subject to probe sonication and forced degradation using HCl. Probe sonication of the liposomes for 298 
10 min was shown to reduce the DMPC liposomes to ~90–100 nm with a PDI of 0.291 ± 0.011 (Figure 299 
6), and HPLC-ELSD analysis did not detect any degradation products resulting from sonication 300 
(Figure 6A). However, degradation products from DMPC were detected with HPLC after forced 301 
degradation (Figure 6B), as represented by a peak at 2.4 min equating to degradation products, as 302 
previously shown by Zhong and Zhang [29]. Zhong et al. were able to show that dipalmitoyl 303 
phosphatidylcholine (DPPC) can degrade into palmitic acid and the lyso forms of DPPC. From our 304 
results, it cannot be confirmed which degradation products we were able to detect; however, the 305 
change in the DMPC peak and the formation of a new peak does suggest lipid degradation. While 306 
the data presented in Figure 6 suggests that the lipids were resistant to degradation via short-term 307 
sonication, previous studies have shown that probe sonication can cause an increase in hydrolysis 308 
and peroxidation of the lipids within the liposome bilayer, which can cause liposome instability, 309 
enhance the membrane permeability, and promote liposome fusion [19,23,34,35]. For more detailed 310 
analysis of lipid degradation, mass spectroscopy would be more beneficial. However, HPLC-ELSD 311 
can also offer insight into potential lipid degradation. 312 
 313 
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Figure 6. Analysis of lipids within DMPC liposomes. DMPC liposomes were prepared and subjected 314 
to (A) probe sonication for 10 min, or (B) forced degradation using HCl. 315 
4. Conclusions 316 
Using HPLC-ELSD, we were able to rapidly and simultaneously quantify lipid concentration 317 
within liposomal systems prepared from a range of lipids, and we have validated and applied this 318 
method to demonstrate high lipid recovery within liposomes prepared by a range of methods. This 319 
demonstrates the applicability of HPLC-ELSD for the rapid quantification of lipids within liposomal 320 
systems for drug and vaccine delivery. 321 
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